Abstract 1284P
Background
Liquid biopsies (LB) are a non-invasive source of tumor molecular information. Here, we evaluate the clinical utility of LB for the management of ALK-positive non-small cell lung cancer (NSCLC) patients using RNA from platelets and extracellular vesicles (EVs), and circulating tumor DNA (ctDNA).
Methods
Blood and tissue samples were collected from 30 ALK-positive, stage IIIB-IV NSCLC patients prior to initiating first-line brigatinib treatment. Nucleic acids from formalin-fixed-paraffin embedded (FFPE) tissue and plasma samples were analyzed by next-generation sequencing (NGS) using the Oncomine Focus Assay or the TruSight Oncology 500 ctDNA panel, respectively. EVs and platelets were isolated from plasma samples by differential centrifugation and RNA within these compartments was evaluated by QuantStudio 3D Digital PCR System and, when possible, by nCounter.
Results
The overall response rate was 93% (95%CI: 75.1, 98.4). Patients were followed for a median of 33.6 months. Median duration of response was 14.7 months. The median progression-free survival (PFS) was 33.8 months (6.2 – NR months) and median overall survival (OS) was not reached (NR). NGS analysis of FFPE samples enabled the detection of ALK fusion variants in all samples. Eleven patients harbored EML4-ALK variant 1 (v1), 5 carried v2, and 7 harbored the V3 and 7 had other variants or a combination of more than one variant. There were no significant differences in survival outcomes according to the type of variant. LB analysis revealed fusion detection rates of 33% using EVs, 17% in platelets, and 71% by ctDNA NGS profiling. Additionally, ctDNA provided information about tumor mutational burden (TMB) and ctDNA levels. Patients with blood TMB below 80 mutation/Mb exhibited significantly improved outcomes in terms of progression-free survival (PFS) (HR= 0.11; 95%CI: 0.02-0.76). Similarly, those with low baseline ctDNA levels (Maximum VAF ≤1%) demonstrated significantly superior PFS (HR= 0.11; 95%CI: 0.02-0.61) and overall survival (OS) (HR= 0.14; 95%CI: 0.03-0.82) compared to counterparts with higher ctDNA levels.
Conclusions
Detection rate by ctDNA profiling is higher compared with RNA-based approaches and it is of prognostic significance.
Clinical trial identification
NCT04223596.
Editorial acknowledgement
Legal entity responsible for the study
Fundacion GECP/Spanish Lung Cancer Group.
Funding
Takeda.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1324P - Durvalumab in treatment-naive, stage IV non-small cell lung cancer (NSCLC) patients (pts), with ECOG performance status (PS) 2-3 and high PD-L1 tumour expression: Results of IFCT-1802 SAVIMMUNE phase II trial
Presenter: Valerie Gounant
Session: Poster session 05
1325P - TRIDENT: Machine learning (ML) multimodal signatures to identify patients that would benefit most from tremelimumab (T) addition to durvalumab (D) + chemotherapy (CT) with data from the POSEIDON trial
Presenter: Ferdinandos Skoulidis
Session: Poster session 05
1326P - Clinical and genomic characteristics of advanced non-small cell lung cancer (aNSCLC) patients (pts) with long-term response to first-line (1L) immunotherapy: A real-world study
Presenter: Sameh Daher
Session: Poster session 05
1327P - Lung immune prognostic index (LIPI) as a guide for addition of chemotherapy in immunotherapy in elderly patients (Pts) with non-small cell lung cancer (NSCLC): NEJ057
Presenter: OSAMU HONJO
Session: Poster session 05
1328P - Dynamic blood immune-inflammatory and radiomic profiling to decode distinct patterns of acquired resistance to immunotherapy in NSCLC patients
Presenter: Giulia Mazzaschi
Session: Poster session 05
1330P - Phase II study of pembrolizumab (pemb) plus plinabulin (plin) and docetaxel (doc) for patients (pts) with metastatic NSCLC after failure on first-line immune checkpoint inhibitor alone or combination therapy: Initial efficacy and safety results on Immune Re-sensitization
Presenter: Yan Xu
Session: Poster session 05
1331P - Efficacy, innovativeness, clinical trials, endpoints, and price of drugs with FDA approval for non-small cell lung cancer (NSCLC)
Presenter: Christoph Michaeli
Session: Poster session 05
1332P - Effects of immune checkpoint inhibitors for EGFR-wild/ALK-negative NSCLC patients with untreated brain metastases
Presenter: Toshihiko Iuchi
Session: Poster session 05
1333P - Prognostic value of circulating nucleosomes during treatment with or without immunotherapy in non-small lung cancer (NSCLC): Results from the NUCLEO-lung study
Presenter: Léa Payen
Session: Poster session 05